ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "ACPA"

  • Abstract Number: 586 • 2016 ACR/ARHP Annual Meeting

    Association Between ACPA Fine Specificity and High Resolution Computed Tomography Lung Changes in Patients with Early Rheumatoid Arthritis

    Vijay Joshua1, Katerina Chatzidionysiou1, Gudrun Reynisdottir1, Aase Hensvold1, Monika Hansson1, Leonor Nogueira2, Guy Serre2, Johan Grunewald3 and Anca I Catrina1, 1Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, 2Unité Différenciation Épidermique et Autoimmunité Rhumatoïde, Unité Mixte de Recherche, INSERM, Toulouse, France, 3Division of Respiratory Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Airways abnormalities that are consistent with inflammation are common in anti-CCP2 positive subjects without inflammatory arthritis. Anti-CCP2 antibodies are associated with high-resolution computed tomography…
  • Abstract Number: 1435 • 2015 ACR/ARHP Annual Meeting

    Central Pain Sensitization in Rheumatoid Arthritis – Role of ACPA?

    Katarzyna Rogoz1, Teresa Fernandez Zafra1, Catia Cerqueira2, Per Johan Jakobsson3, Katalin Sandor4, Erwan Le Maître5, Magnus LA. Andersson6, K. Lundberg7, Camilla Svensson4 and Jon Lampa8, 1Physiology and pharmacology, Karolinska Institutet, Stockholm, Sweden, 2Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 3Department of Medicine, Unit of Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 4Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, 5Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 6Dep of Neurology, Karolinska Institute, Stockholm, Sweden, 7Karolinska Institute, Stockholm, Sweden, 8Dep of Medicine, Rheumatology unit, Karolinska Institute, Karolinska Institute, Stockholm, Sweden

    Background/Purpose: Chronic pain continues to be a significant problem for patients with rheumatoid arthritis (RA), even when the disease is medically controlled or in remission.…
  • Abstract Number: 3100 • 2015 ACR/ARHP Annual Meeting

    Anti-RA33 Citrullinated/Native Double-Reactive Antibodies Identify Patients with the Highest Risk of Radiographic Progression in Rheumatoid Arthritis

    Maximilian F. Konig1, Jon Giles2, Peter A. Nigrovic3 and Felipe Andrade1, 1Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, 2Rheumatology, Columbia University Medical Center, NY, NY, 3Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Antibodies against RA33 (hnRNP A2/B1) were one of the earliest antigen specificities identified in rheumatoid arthritis (RA). Unlike the erosive disease associated with anti-citrullinated…
  • Abstract Number: 1510 • 2015 ACR/ARHP Annual Meeting

    The Association Between HDL Cholesterol Efflux Capacity, Citrullinated ApoA1 and Anti-Citrullinated ApoA1 Antibodies in Rheumatoid Arthritis

    Katherine Liao1, Jing Cui1, Christopher Rhodes2, Lauren J. Lahey2, Martin Playford3, I-Hsin Kuo1, Michelle Frits1, Christine Iannaccone1, Jonathan S. Coblyn4, Michael Weinblatt1, Nancy Shadick5, Nehal N. Mehta3 and Jeremy Sokolove2, 1Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, 2Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, 3NHLBI, National Institutes of Health, Bethesda, MD, 4Brigham & Women's Hospital, Boston, MA, 5Division of Rheumatology, Immunology & Allergy, Brigham & Women's Hospital, Boston, MA

    Background/Purpose: High density lipoprotein (HDL) cholesterol efflux capacity measures how well HDL particles remove cholesterol from lipid-laden macrophages, such as those found in atherosclerotic plaques. …
  • Abstract Number: 3172 • 2015 ACR/ARHP Annual Meeting

    Effect of Anti Citrullinated Protein Antibodies on Periarticular and Systemic Bone Mass in Early Arthritis Patients

    Irene Llorente Cubas*1, Leticia Merino-Meléndez2, Ana M. Ortiz Garcia2, Eugenio Escolano3, Teresa Velasco1, Elena García2, Esther Vicente-Rabaneda2, Alberto Garcia-Vadillo4, Rosario Garcia-Vicuña4, Isidoro González-Alvaro*2 and Santos Castañeda*2, 1Rheumatology, H.U La Princesa, Madrid, Spain, 2Rheumatology, H.U. La Princesa, Madrid, Spain, 3Radiology Department, H.U La Princesa, Madrid, Spain, 4Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain

    Background/Purpose: Recently it has been described that anti citrullinated protein antibodies (ACPA) can induce differentatiomn and activation of osteoclasts even before arthritis onset (1,2). The…
  • Abstract Number: 1594 • 2015 ACR/ARHP Annual Meeting

    No Association of Anti-Citrullinated Peptide Antibodies with Coronary Artery Calcification in Two Rheumatoid Arthritis Cohorts without Clinical Cardiovascular Disease

    Laura Geraldino-Pardilla1, Jon T. Giles2, Jeremy Sokolove3, Afshin Zartoshti4, WH Robinson5 and Joan M. Bathon6, 1Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, 2Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, 3Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, 4Rheumatology, Columbia University Medical Center, NY, NY, 5Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 6Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY

    Background/Purpose: Citrullinated proteins have been found in atherosclerotic plaques. However, contradictory results currently exist regarding the association of anti-citrullinated peptide antibodies (ACPAs) with coronary artery…
  • Abstract Number: 3253 • 2015 ACR/ARHP Annual Meeting

    The Predictive Value of Antibodies to Cyclic Citrullinated Peptide in Two Prospective Early Rheumatoid Arthritis Cohorts 10 Years Apart

    Alf Kastbom1, Michael Ziegelasch1, Ingrid Thyberg1, Birgir Arge2, Klara Martinsson1, Olle Svernell3, Åsa Häggström4, Per Salomonsson5, Britt-Marie Nyhäll-Wåhlin6, Sören Transö7, Claudia Jacobs8 and Thomas Skogh1, 1IKE/Rheumatology, Linköping University, Linköping, Sweden, 2Rheumatology clinic, Eskilstuna Hospital, Eskilstuna, Sweden, 3Rheumatology Dpt, Västervik Hospital, Västervik, Sweden, 4Rheumatology clinic, Kalmar Hospital, Kalmar, Sweden, 5Rheumatology Clinic, Örebro University Hospital, Örebro, Sweden, 6Department of Rheumatology, Falun Hospital, Falun, Sweden, 7Rheumatology Clinic, Ryhov Hospital, Jönköping, Sweden, 8Rheumatology Dept, Oskarshamn Hospital, Oskarshamn, Sweden

    Background/Purpose: Antibodies to cyclic citrullinated peptides (anti-CCP) associate with a more severe rheumatoid arthritis (RA) disease course, and therefore have influence on therapeutic decisions. By…
  • Abstract Number: 151 • 2015 ACR/ARHP Annual Meeting

    Residual Synovitis in Ultrasound (US) Is Associated with an Evolution Towards Rheumatoid Arthritis  (RA) in Patients with Inflammatory Polyarthralgia without ANTI-Citrulinated Antibodies (ACPA)

    Pascal Zufferey1,2,3, Claudia Rebell Jr.4, Alexandre Dumusc5, Mauro lucini4, Juerg Hains6, Alexander K. So Sr.7 and Charles Benaim8, 1Rheumatology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, 2Pierer Decler, Chuv, Lausanne, Switzerland, 3Rhu /Dal .Chuv, Rheumatology, Lausanne, Switzerland, 4DAL, RHU/CHUV, lausanne, Switzerland, 5RHU/CHUV, lausanne, Switzerland, 6DAL, RHU/CHUV, Lausanne, Syria, 7Service De Rhumatologie, CHUV, Lausanne, Switzerland, 8DAL, MPR, Lausanne, Switzerland

    Background/Purpose: In ACPA positive patients, subclinical synovitis as observed by US has been demonstrated in pre RA patients and seems to be predictive for future…
  • Abstract Number: 1618 • 2015 ACR/ARHP Annual Meeting

    The Protective Effect of HLA-DRB1*13 Alleles during Specific Phases in the Development of ACPA-Positive RA

    J. van Heemst1, A.H. Hensvold2, X. Jiang2, H. van Steenbergen1, L. Klareskog2, T. W. J. Huizinga1, A.H.M. van der Helm- van Mil1, A.I. Catrina2, René E. M. Toes1, K. Lundberg2 and Diane van der Woude1, 1Leiden University Medical Center, Leiden, Netherlands, 2Karolinska Institute, Stockholm, Sweden

    Background/Purpose: HLA-DRB1*13 alleles are associated with protection from anti-citrullinated protein antibody (ACPA-)positive rheumatoid arthritis (RA). It is however unknown at which phase of disease development…
  • Abstract Number: 479 • 2015 ACR/ARHP Annual Meeting

    How to Recruit Anti-CCP Positive Patients from Primary Care

    Jackie L. Nam1, Laura Hunt1, Elizabeth M.A. Hensor1 and Paul Emery1,2, 1NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom

    Background/Purpose: Around 1% of the population test positive for anti-cyclic citrullinated peptide (anti-CCP) antibodies. This biomarker predicts progression to rheumatoid arthritis (RA) but over a…
  • Abstract Number: 1641 • 2015 ACR/ARHP Annual Meeting

    B Cell Depletion with Rituximab in Patients with Rheumatoid Arthritis: Multiplex Bead Array Reveals Kinetics of IgG and IgA Autoantibodies to Citrullinated Antigens

    Geraldine Cambridge1, Lauren J. Lahey2, Maria J. Leandro1, William H. Robinson3 and Jeremy Sokolove4, 1Rheumatology, University College London, London, United Kingdom, 2Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, 3VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 4Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA

    Background/Purpose: Seropositivity for rheumatoid factors and anti-citrullinated (Cit) protein antibodies (ACPA) are the strongest predictor for clinical response to rituximab (RTX) in rheumatoid arthritis (RA).…
  • Abstract Number: 499 • 2015 ACR/ARHP Annual Meeting

    Efficacy of Tocilizumab Monotherapy in Patients with RA Is Not Influenced By ACPA Positivity

    Manfred Herold1, Peter Fasching2, Winfried Graninger3, Raimund Lunzer4, Omid Zamani5 and Burkhard Leeb6, 1Internal Medicine VI, Medical University of Innsbruck, Austria, Innsbruck, Austria, 2Department of Internal Medicine V, Wilhelminen Hospital Vienna, Vienna, Austria, 3Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, 4Department of Internal Medicine, Hospital Barmherzige Brüder Graz-Eggenberg, Graz, Austria, 5Rheumazentrum Favoriten Vienna, Wien, Austria, 62nd Dept. of Medicine, State Hospital Stockerau, Center for Rheumatology Lower Austria, Stockerau, Austria

    Background/Purpose: Rheumatoid arthritis (RA) patients with anti-citrullinated peptide antibodies (ACPA) need a more aggressive therapy (1). Tocilizumab (TCZ) seems to be the biologic with best…
  • Abstract Number: 2020 • 2015 ACR/ARHP Annual Meeting

    Elevated BMI and ACPA Together Increase RA Risk and Independently Accelerate Time to RA

    Sara K. Tedeschi1, Jing Cui2, Elizabeth V. Arkema3, Jeffrey A. Sparks1, Elizabeth W. Karlson1 and Karen H. Costenbader1,4, 1Rheumatology, Brigham & Women's Hospital, Boston, MA, 2Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, 3Karolinska Institutet, Stockholm, Sweden, 4Rheumatology, Immunology & Allergy, Brigham & Women's Hospital, Boston, MA

    Background/Purpose: Obesity and anti-citrullinated peptide antibodies (ACPA) are risk factors for RA. We investigated whether body mass index (BMI) and ACPA interact in determining RA…
  • Abstract Number: 515 • 2015 ACR/ARHP Annual Meeting

    Are Changes in Autoantibody Levels Reflecting Change in Prognosis of Rheumatoid Arthritis?

    Manuel Unger1, Farideh Alasti1, Paul Studenic1, Josef S. Smolen2,3 and Daniel Aletaha1, 1Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, 22nd Department of Medicine, Hietzing Hospital, Vienna, Austria, 3Department of Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria

    Background/Purpose: The presence of rheumatoid factor (RF) and antibodies against citrullinated peptides (ACPA) is associated with progression of joint damage in patients with rheumatoid arthritis…
  • Abstract Number: 2565 • 2015 ACR/ARHP Annual Meeting

    ACPA Specific IVIG Attenuate Collagen Induced Arthritis in Mice

    Shaye Kivity1, Nina Svetliscky1, Qusim Odeh1, Smadar Gertel1, Howard Amital1, Omer Gendelman1, Iris Barshack2, Alexander Volkov2, Eran Bar-Meir3, Miri Blank1 and Yehuda Shoenfeld4, 1Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, 2Sheba Medical Center, Institute of Pathology, affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, 3Plastic surgeon Poria Medical Center affiliated to Faculty of medicine in the Galilee Bar-Ilan university, Poria, Israel, 4Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, affiliated to affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel

    Background/Purpose: Administration of intravenous-immunoglobulin (IVIg) is a recognized safe and efficient immunomodulatore therapy for many autoimmune diseases. Anti-idiotypic antibody binding to pathogenic autoantibodies was proposed…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 13
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology